CTLA4 and neoplasm: In contrast, anti-CTLA-4 antibodies not only block ligand engagement by binding CTLA-4 with high affinity but may also deplete or functionally inhibit Tregs within the TME, thereby alleviating immunosuppression and potentiating anti-tumor immunity.